Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2021-01-24Journal
International Journal for Parasitology. Drugs and Drug ResistancePublisher
Elsevier Ltd.Type
Article
Metadata
Show full item recordAbstract
Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening. © 2021 The AuthorsRights/Terms
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.Identifier to cite or link to this item
http://hdl.handle.net/10713/14730ae974a485f413a2113503eed53cd6c53
10.1016/j.ijpddr.2020.12.004